Max Denning, MD, MBA

Max Denning leads the global diabetes development program for orforglipron, the first non-peptide oral GLP-1 receptor agonist to successfully complete multiple Phase 3 trials. Unlike currently available peptide based GLP-1 therapies, orforglipron can be taken orally, at any time of day, and without food or water restrictions—addressing both patient convenience and manufacturing scalability challenges facing the GLP-1 class. The ACHIEVE program has enrolled over 6,000 participants globally, with regulatory submissions anticipated in 2026.

Through Lilly's Accelerated R&D Leadership Program, prior to his current role, Max has worked across regulatory affairs, patient safety, and clinical development, giving him a comprehensive view of how innovative therapies navigate from lab to patient.

Max holds an MD from Oxford, an MSc in Patient Safety from Imperial College London, and an MBA from Stanford, where he was a Knight-Hennessy Scholar.

Inessa Lurye, MBA, MPP

Inessa Lurye is a product leader and healthcare innovator. She is the VP of Product, Women’s Health at ŌURA, where she helps create a product experience tailored to the unique needs of women. Most recently, she led new program development for all software and connected hardware products at Hinge Health - creating new care solutions for those experiencing musculoskeletal pain. She also led the team that developed Hinge Health’s Women Pelvic Health program, the largest program for digital pelvic healthcare in the US. She was named the 2023 Product Management Leader of the Year (2nd place) by Women in Tech and was a finalist for the 2024 Femtech World Leader of the Year Award. Over the last 19 years, she has held product leadership roles at multiple venture-funded startups, led healthcare policy in city government, consulted at McKinsey & Company, and served as an advisor and investor for startups focused on women’s health. Inessa holds an MBA with the Highest Distinction from the Harvard Business School, an MPP from the Kennedy School of Government, and a BA, Phi Beta Kappa, from Swarthmore College.

Florence Porterfield, MD

Florence Porterfield is an Instructor in Medicine at Harvard Medical School and an Associate Physician in the Department of Medicine at Massachusetts General Hospital, where she specializes in obesity medicine. Her clinical work focuses on evidence-based treatment of obesity and metabolic disease, and her research investigates the intersection of obesity pharmacotherapy, cancer risk, and long-term weight maintenance.

A graduate of the Perelman School of Medicine at the University of Pennsylvania, Dr. Porterfield completed her internal medicine residency and fellowship in obesity medicine at Massachusetts General Hospital. She also serves as a clinical advisor to Alnu Health, a digital health startup using AI to deliver personalized lifestyle coaching for patients on GLP-1 therapy.

Jesse Kesner

Jesse Kesner is the Co-Founder and CEO of Alnu Health, a digital health startup helping patients own their health journeys and sustain outcomes while on GLP-1 therapy. Before launching Alnu, Jesse was an investor at L Catterton and a consultant at McKinsey & Company, where he also spent time on secondment to Peloton’s Strategy team shaping growth initiatives in the post-COVID era. A current MBA candidate at Harvard Business School, Jesse brings a deep passion for combining technology, clinical insight, and behavioral science to make metabolic health more accessible and sustainable.